IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.

Uwe Platzbecker,Rami S. Komrokji,Pierre Fenaux,Amer M. Zeidan,Mikkael A Sekeres,Michael R. Savona,Yazan F. Madanat,Laurie Sherman,Souria Dougherty,Libo Sun,Fei Huang,Ying Wan,Aleksandra Rizo,Tymara Berry,Faye Feller,Valeria Santini

IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.

2021

Uwe Platzbecker
Rami S. Komrokji
Pierre Fenaux
Amer M. Zeidan
Mikkael A Sekeres
Michael R. Savona
Yazan F. Madanat
Laurie Sherman
Souria Dougherty
Libo Sun
Fei Huang
Ying Wan
Aleksandra Rizo
Tymara Berry
Faye Feller
Valeria Santini

TPS7056Background: Current treatment options for red blood cell (RBC) transfusion-dependent (TD) patients (pts) with lower risk (LR) myelodysplastic syndromes (MDS) relapsed after or refractory to ...

Keywords:

Medicine
Imetelstat
Erythropoiesis-stimulating agent
Internal medicine
Phases of clinical research
Oncology
Myelodysplastic syndromes
Refractory
transfusion dependence
Lower risk
Red blood cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations